Last reviewed · How we verify

TIPRANAVIR — Competitive Intelligence Brief

TIPRANAVIR (TIPRANAVIR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Protease Inhibitor [EPC].

marketed Protease Inhibitor [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

TIPRANAVIR (TIPRANAVIR).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
TIPRANAVIR TARGET TIPRANAVIR marketed Protease Inhibitor [EPC] 2005-01-01
PF-07321332 Dose 5 pf-07321332-dose-5 Pfizer marketed Protease inhibitor Main protease (MPro) of SARS-CoV-2 Pending regulatory approval
Paxlovid (Copackaged) Nirmatrelvir Pfizer marketed Antiviral protease inhibitor SARS-CoV-2 main protease (Mpro, 3CLpro, nsp5 protease) 2023-01-01
Victrelis BOCEPREVIR Merck & Co. marketed Hepatitis C Virus NS3/4A Protease Inhibitor Chymase 2011-01-01
Prezista DARUNAVIR Janssen Prods marketed Protease Inhibitor [EPC] Multidrug resistance protein 1 2006-01-01
Reyataz ATAZANAVIR Bristol-Myers Squibb marketed Protease Inhibitor UDP-glucuronosyltransferase 1-1 2003-01-01
Lexiva FOSAMPRENAVIR GSK marketed Protease Inhibitor 2003-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Protease Inhibitor [EPC] class)

  1. · 1 drug in this class
  2. Janssen Prods · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TIPRANAVIR — Competitive Intelligence Brief. https://druglandscape.com/ci/tipranavir. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: